Skip to content
You can now search across every topic, entity and event.What's new
UK Startups and Innovation
4JUL

LSIMF sends £80m+ to four regional sites

3 min read
11:24UTC

Barnstaple, Birmingham, Haverhill, Hengoed. Every Life Sciences Innovative Manufacturing Fund cheque this round landed outside the Golden Triangle, and the geography is the whole point.

TechnologyDeveloping
Key takeaway

LSIMF's regional spread turns life sciences capex into a deliberate tool of industrial geography rather than a research grant.

The Life Sciences Innovative Manufacturing Fund (LSIMF) allocated over £80m to four UK sites on 14 April 2026: Accord Healthcare in Barnstaple received over £45m for generic and bipolar-medicine manufacturing; the University of Birmingham's Precision Health Technologies Accelerator received £10m for cell and gene therapy and mRNA biomanufacturing; Codis in Haverhill received funding for a spray-drying facility for cancer and neurodegenerative therapies, creating 29 new jobs; and Norgine in Hengoed, South Wales, received over £20m for pharmaceutical facility expansion. 1

LSIMF sits inside the UK's broader life sciences industrial strategy and is administered by DSIT. Its remit is manufacturing capex rather than research grants, which matters because Britain's historic problem is not inventing medicines but making them at commercial scale. Accord's Barnstaple facility alone covers 9% of NHS prescriptions by volume; losing it offshore would be a sovereignty problem before it became an employment one. The fund deliberately steers capex away from the research-heavy Oxford-Cambridge-London corridor toward regions with slower wage inflation and available industrial land.

DSIT designed the geographic pattern deliberately. Grant award counts across UK innovation funding are at a 10-year low even as average grant size rises; the policy response has been to consolidate fewer, larger cheques into regional sites that would not otherwise attract private pharmaceutical capex. Devon, Suffolk, Birmingham and South Wales each get a named beneficiary and a dated announcement. Cumulative UK life sciences investment in 2026 stands at £600m; DSIT is targeting £1bn by summer, leaving roughly £400m still to be announced before July with the Golden Triangle deliberately excluded from the remaining pool.

For operators in regional pharma manufacturing, the signal is that LSIMF rounds are now a forecastable policy pipeline rather than a one-off window. For Golden-Triangle biotech, the absence of any London, Oxford or Cambridge cheque this week is itself a commissioning note.

Deep Analysis

In plain English

The government has given over £80m to four pharmaceutical factories in Devon, Birmingham, Suffolk, and South Wales. These are places that usually miss out when big innovation grants are handed out, which tend to cluster around London, Oxford, and Cambridge. Accord Healthcare in Barnstaple makes medicines that cover nearly one in ten NHS prescriptions, meaning millions of people rely on it directly. The grants are designed to modernise the factories and create jobs outside the south-east.

Deep Analysis
Root Causes

NHS procurement of generic medicines is dominated by import from Indian and Eastern European manufacturers; Accord Healthcare's Barnstaple facility covers 9% of NHS prescriptions by volume, but the supply chain remains exposed to logistics disruption because no strategic reserve requirement exists in UK pharmaceutical regulation, unlike the 90-day mandatory reserves France and Germany operate under EU Directive 2001/83/EC.

The UK's post-Brexit exclusion from the EMA's pan-European medicines stockpile system (ECEI) removed a buffer that previously smoothed regional supply shocks; the LSIMF is partly a domestic resilience response to that regulatory gap.

What could happen next?
  • Consequence

    If Codis in Haverhill hires all 29 announced jobs within 12 months and files for a follow-on LSIMF grant in the next funding round, it will become the benchmark case for whether small-site LSIMF investment produces additionality or simply supports existing operators.

    Short term · 0.65
  • Risk

    The £400m still to be announced before July 2026 under the £1bn LSIMF target, if concentrated in the three remaining sites, creates a planning and construction queue that will collide with UK construction capacity shortages, likely slipping at least two facilities by 12-18 months.

    Medium term · 0.6
  • Opportunity

    Norgine's £20m Hengoed expansion positions South Wales as a candidate for the next round of LSIMF allocations targeting active pharmaceutical ingredient (API) production, which the UK currently imports at 95% dependency on Asian suppliers.

    Medium term · 0.5
First Reported In

Update #2 · Britain's innovation pipe leaks at both ends

DSIT· 22 Apr 2026
Read original
Causes and effects
This Event
LSIMF sends £80m+ to four regional sites
The LSIMF allocation sets a deliberate precedent for non-Golden Triangle life sciences capital, with cumulative 2026 UK investment now at £600m against a £1bn summer target.
Different Perspectives
Institute of Physics
Institute of Physics
The Institute has long argued STFC's national-laboratory infrastructure, not its grant programmes, is the binding constraint on UK physics output, and warns mothballing capacity like Clara removes capability that cannot be rebuilt on a four-year cycle. It represents the discovery-science community absorbing the reallocation the Bank's equity cheques do not touch.
Helsing
Helsing
The Munich-headquartered defence-AI firm chose Plymouth over Continental sites for a £350m manufacturing plant building underwater surveillance gliders, alongside its record raise. Its choice of postcode signals confidence in UK manufacturing capacity for defence hardware even as it looks abroad for the capital financing that hardware.
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
Dragoneer Investment Group, Lightspeed Venture Partners and Iconiq
The three US growth-capital firms backed Helsing's $1.8bn round at an $18bn valuation, more than doubling the mark set only a year earlier, with demand reportedly exceeding the capital on offer. Their money, not a UK sovereign vehicle, is what funds the Plymouth plant, extending a pattern of foreign capital underwriting British defence-hardware manufacturing this cycle.
British Business Bank
British Business Bank
The Bank wrote its largest-ever direct life-sciences cheque into Alchemab and added a £6.5bn SME lending guarantee the same week UKRI confirmed the STFC cuts. It is deploying an April mandate change letting it lead venture rounds and invest directly up to £60m per company, treating equity extension rounds and small-business debt as newly within its risk appetite.
Daphni
Daphni
The Paris seed fund joined Speedinvest and three UK backers in Astral Systems' GBP23m Series A for modular fusion reactors, one of the round's five European co-investors betting on lab-to-market fusion ahead of any working commercial reactor. Unlike CuspAI's all-foreign cap table, this round kept a UK lead investor in Mercia Ventures.
EQT
EQT
EQT, appointed by the European Innovation Council to run the EUR5bn Scaleup Europe Fund, entered advanced talks for a further CuspAI stake reported on 3 July, the fund's first pursuit of a UK-founded winner. A closed deal would put EU sovereign capital, not a UK vehicle, on the cap table of a company Britain's own funds passed over.